Investing to Find Cures for Cancer

Juno’s pipeline of therapeutic T cell product candidates apply our CAR and TCR technologies against a variety of cancer targets.

Juno Therapeutics Current Pipeline

ALL=acute lymphoblastic leukemia; AML=acute myeloid leukemia; CLL=chronic lymphocytic leukemia; NHL=non-Hodgkin lymphoma; NSCLC=non-small cell lung cancer

For Juno’s policy on Expanded Access to Investigational Therapies click here. (PDF)



Juno’s CD19 CAR and WT-1 TCR clinical programs include multiple product candidates in clinical development for several hematologic malignancies in adults and children.


Juno is investing in continued technology improvements as well as CAR and TCR product candidates targeting multiple cancer types.

Therapeutic Areas

Juno is developing cell-based therapies across various cancer types and understanding the technology’s application to other diseases.